US.: +1-252-477-1362
UK.: +44-203-957-8553
AUS.: +61-2-4786-0457
INDIA: +91-848-285-0837
The global pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition and patent cliffs. Innovation is of vital importance for steady growth of pharmaceutical companies. Pharmaceutical companies have been mainly dependent on a few blockbuster molecules. However,with rapid decline in research and development (R&D) productivity and non-conducive regulatory environment, companies need to find... View more
The global pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition and patent cliffs. Innovation is of vital importance for steady growth of pharmaceutical companies. Pharmaceutical companies have been mainly dependent on a few blockbuster molecules. However,with rapid decline in research and development (R&D) productivity and non-conducive regulatory environment, companies need to find different avenues of growth. The patent expiry of blockbuster drugs is expected to pave way for generics. Due to difference in genetic composition of varied individuals, innovation is becoming more complex.This is influencing players offering complementary products and services to collaborate for new product development.
There are four major factors that are impacting the value creation in pharmaceutical industry:
Demand for personalized medicines is increasing in order to ensure effective treatment of various diseases
Investments in R&D for oncology and NCDs are increasing globally in order to provide cost-effective solutions available to ailing patients.
Market Challenges
The industry is facing certain challenges such as patent cliff, cost pressure and regulatory uncertainties across the globe. This is hindering market growth to a certain extent. Moreover, regulatory authorities are becoming more stringent with the drug approval process. However, with respect to drugs for rare diseases, the FDA has offered a fast-track approval process. Moreover, demand for cost-effective treatment for chronic and non-communicable diseases such as diabetes, hypertension, thyroid disorder, obesity, and cancer is increasing. However, there is a dearth of strong products in the pipeline that offer better treatment option with fewer side effects. The fear of side effects and long-term treatment costs is encouraging patients to shift to alternative therapies.
Combating Challenges
Market players need to combat these challenges and keep their pace with the industry to sustain their market share. Mergers, acquisitions, and divestitures of products, companies or business division is a rapidly emerging trend in the market to combat prevalent challenges in the market.Companies are more focused in terms of therapy areas and hence, are divesting less focused therapy businesses. A good example is the swap deal between GSK and Novartis in 2015.
Moreover, pharmaceutical companies are investing in consumer health products,with increasing consumer’s health awareness and emerging trend of self-medication. These trends are encouraging pharmaceutical companies to enter the OTC market and leverage their brand equity among the doctors, chemists and consumers. Companies such as GlaxoSmithKline, Cipla, Pfizer, Merck, Sun Pharma, and Abbott have a focused division or subsidiary for consumer healthcare products and markets.
Moreover, to combat increasing cost pressure, companies are evolving their distribution channel. Establishing facilities or presence through collaboration in regional markets has helped companies meet local demand with reduced costs and delivery time. Emergence of e-pharmacy has resulted in creation of a separate team in the organization to service consumers ordering medicines online. Moreover, companies are connecting with consumers through social media, which helps improve brand visibility. The distribution channel has thus evolved significantly from the decade old channel consisting of only wholesalers and physical retail shops.
Patient-centricity
Patients are increasingly becoming well informed and organized, sometimes demanding for a particular product from prescribers. Therefore, companies need to be more patient-centric in their approach and provide quality care to consumers. Pharmaceutical companies are focusing on established direct to consumer distribution channels and establishing a more strong relationship with them. Moreover, companies are creating a good purchase experience for consumers through different offerings such as post-purchase medical services, engaging the patient through social media and events, and providing regular product alerts and refilling services.
Growth in Emerging Economies
The pharmaceutical industry is rapidly expanding in emerging economies such as Asia Pacific, Africa, and Latin America. These regions possess immense potential for growth of pharmaceutical companies, owing to inadequate access to medicines, growing population and increasing incidence of non-communicable diseases (NCDs). Besides, demand for contract research and manufacturing is also high in these regions. China and India are the largest emerging markets for CRO and CMO. Companies are highly dependent on China for API supply owing to low purchase cost. Overdependence on a single country can pose a challenge for the pharmaceuticals sector in the near future. Therefore, other emerging countries such as India, Brazil and South Africa are encouraging investments in their country. Besides, global companies are establishing their facilities in Asia Pacific, Middle East and Latin America regions to enable close monitoring and servicing of lucrative regional markets.
Conclusion
Pharmaceutical companies need to focus on an integrated, patient-centric, value-driven approach along with technology integration and strategic partnerships in order to capitalize on lucrative growth opportunities in the market. Major global players in the market include Pfizer Inc., Merck & Co., Inc., Bayer AG, GlaxoSmithKline plc., Sanofi, F. Hoffmann-La Roche AG, AstraZeneca plc. and Novartis AG.
There is a paradigm shift in process in the global pharmaceutical industry from product to a ‘Prodice’ (Product and Service) model, to offer affordable, accessible and quality care to patients.View less
Published Date : Dec 2024
The Global Somatic Therapy Market is estimated to be valued at USD 3.41 Bn in 2024 and is expected to reach USD 10.40 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 17.32% from 2024 to 2031. The global somatic therapy market has been witnessing steady ... View more
Published Date : Dec 2024
The Global Exosomes Skincare Market is estimated to be valued at USD 380.1 Mn in 2024 and is expected to reach USD 729.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031. Exosomes ... View more
Published Date : Dec 2024
The Global Biosimilar Contract Manufacturing Market is estimated to be valued at USD 10.70 Bn in 2024 and is expected to reach USD 30.03 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 16% from 2024 to 2031. Biosimilars are biological products designed ... View more
Published Date : Dec 2024
Global biologics market is estimated to be valued at USD 522.1 Mn in 2024 and is expected to reach USD 1,044.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031. Biologics refers to medicines created from living organisms that are ... View more
Published Date : Dec 2024
The global diabetic retinopathy market is estimated to be valued at USD 9.30 Bn in 2024 and is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. Diabetic retinopathy is a medical condition in which damag... View more
Published Date : Dec 2024
Global mitral valve disease market is estimated to be valued at USD 2.80 Bn in 2024 and is expected to reach USD 5.12 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9% from 2024 to 2031. Mitral valve disease refers to conditions that affect the mitral ... View more
Published Date : Dec 2024
The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031. Interleukin inhibitors are biologics that block or dam... View more
Published Date : Dec 2024
The global vitrification market is estimated to be valued at USD 9.30 Bn in 2024 and is expected to reach USD 26.51 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 15% from 2024 to 2031. The global vitrification market is witnessing a steady growth owin... View more
Published Date : Dec 2024
Global bone morphogenetic protein market is estimated to be valued at USD 342.3 Mn in 2024 and is expected to reach USD 444.5 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.8% from 2024 to 2031. Global bone morphogenetic protein market has been witne... View more
Published Date : Dec 2024
The global whole exome sequencing market is estimated to be valued at USD 1.80 Bn in 2024 and is expected to reach USD 4.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.8% from 2024 to 2031. Whole exome sequencing is a powerful technology that all... View more
Published Date : Dec 2024
Global paracetamol IV market is estimated to be valued at USD Mn 838.1 Mn in 2024 and is expected to reach USD Mn 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031. Paracetamol, also known as acetaminophen, is among the most... View more
Published Date : Dec 2024
The global lactated ringers injection market is estimated to be valued at USD 510.1 Mn in 2024 and is expected to reach USD 762.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031. Lactated ringers injection is one of the most commo... View more
Published Date : Nov 2024
Global peritoneal dialysis market is estimated to be valued at USD 9.42 Bn in 2024 and is expected to reach USD 13.90 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031. Global peritoneal dialysis market growth is driven by rising pr... View more
Published Date : Nov 2024
The global photobiomodulation market is estimated to be valued a USD 230.3 Mn in 2024 and is expected to reach USD 455.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.Photobiomodulation or low-level light therapy is a treatment... View more
Published Date : Nov 2024
The global vertigo treatments market is estimated to be valued at USD 1.53 Bn in 2024 and is expected to reach USD 2.24 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031. Vertigo refers to a condition where a person feels as if they... View more
Published Date : Nov 2024
The global hemochromatosis market is estimated to be valued at USD 1.60 Bn in 2024 and is expected to reach USD 2.41 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031. Several factors such as increasing prevalence of hereditary h... View more
Published Date : Nov 2024
The global concussion market is estimated to be valued at USD 6.82 Bn in 2024 and is expected to reach USD 10.20 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031. The global concussion market is expected to witness significant grow... View more
Published Date : Nov 2024
The global therapeutic contact lenses market is estimated to be valued at USD 4.91 Bn in 2024 and is expected to reach USD 7.90 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031. Therapeutic contact lenses are specialized lenses presc... View more
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.